by the Scottish Toxoplasma Reference Laboratory). All of the assays were performed by three The detection of specific IgM antibodies to Toxoplasma gondii is a recognised indicator for recent or current infection. Recently, great public interest has focused on T gondii infection in pregnancy. Many laboratories will be faced with increased demands for tests and it may be difficult for reference laboratories to produce sufficient quantities of their in-house tests.'2 Therefore, the relative performances and uses of commercial assays require critical assessment, and this information will be of value to many local laboratories.
One The substrate in the Abbott kit was 0-phenylenediamine and optical density was read at 492 nm. All of the other assays used 3,3',5,5',-tetramethylbenzidine and were read at 450 nm.
Abbott TOXO-M EJA Kit (Abbott Laboratories, Maidenhead): Unlike all of the other assays which used microtitre strips, in this assay the capture antibody was coated on to beads. Each run included one high positive, one negative, and three low positive controls. The threshold was taken as half the mean absorbance of the low positive controls. Equivocal results had an absorbance between 40-50% of the low positive.
Biostat Human (Biostat Diagnostics, Stockport): This indirect immunoassay was performed in strips of eight flat-bottomed wells coated with Toxoplasma antigen. Competition from Toxoplasma specific IgG or rheumatoid factor in the specimen was prevented by incorporating antihuman IgG in the sample diluent buffer. In each run two positive and two negative controls were tested. The threshold value was calculated by adding the mean negative value to a fifth of the positive control value.
Mastazyme -TOXO IgM (Mast Diagnostics, Bootle): This indirect assay was based on Toxoplasma antigen coated strips of eight flatbottomed wells. Specific IgG antibodies were removed by pretreatment with Mastsorb, containing goat anti-human IgG. Duplicate positive and triplicate negative controls were tested in each run. The sum of the mean positive and mean negative control absorbances were multiplied by a factor, supplied with each kit, to produce a cutoff value. Patient sera with an absorbance between the cutoff and 0-1 + cutoff value were considered borderline; those above this range were positive. The assays were rated on several criteria as described by others. We are aware that some of our conclusions differ from previous results. We were unable to confirm the false positive results with the Northumbria assay.4 It has been claimed that the Abbott assay has a high sensitivity,5 but we find that it has a low sensitivity. The explanation is that sensitivity is relative and the previous study did not assess the Mercia or Northumbria assays. The constant arrival of new assays on the market, with their accompanying salespersons, are a source of many queries from local laboratories to reference laboratories. Perhaps it is time for the establishment of a national system for testing new assays.
In conclusion, our results show that the commercial assays have a range of characteristics. Our study has provided detailed, objective information which should be of use to local laboratories. We recommend that those laboratories investigating toxoplasma infection should have three tests: one IgG and two IgM (low and high sensitivity). This study has placed the commercial assays in relevant groups. It is up to local laboratories, with a consideration of their local circumstances, to select the most appropriate assays.
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